Guides
What to expect: from enquiry to follow-up
There is no standard journey for an investigational cell intervention. A defensible process begins with product and regulatory verification, independent assessment and written responsibilities before travel or payment.
The first contact should collect enough information to decide whether a formal medical review is appropriate, not declare you a candidate. Do not send unnecessary sensitive records. Ask who receives the data, who will review it and how it is protected.
Before an offer is interpreted, obtain the exact diagnosis, proposed product, cell source, processing, dose, route, indication and legal route. Check whether the use is authorised, part of an authorised clinical trial or covered by a patient-specific national exemption. A study listing, clinic licence or ATMP label is not a substitute for that check.
Have an independent clinician review the current standard of care, alternatives, contraindications and whether delaying established treatment could cause harm. Eligibility can only be assessed against a lawful product label or an approved protocol; it should not be inferred from an online questionnaire alone.
For a clinical trial, verify the sponsor, EU trial number, recruitment status, sites, protocol summary and ethics or authority decision in the EMA Clinical Trials Information System. Registration is not evidence that the intervention works, and a recruiting record does not guarantee eligibility.
Before any procedure, informed consent should state the investigational status, reasonably foreseeable risks, alternatives, costs, compensation or insurance arrangements, follow-up and who manages complications. You should receive enough time to ask questions and seek a second opinion without sales pressure.
After administration, obtain a dated record of the exact product or procedure, dose, route, batch or traceability identifiers where applicable, immediate observations and medicines. Do not accept a generic certificate in place of the clinical record.
Follow-up should be defined before treatment. Agree objective measures relevant to the condition, the assessment schedule, adverse-event reporting, access to results and communication with your usual clinician. There is no universal timetable for improvement, and absence of an early change does not prove either success or failure.
Request a written, itemised financial statement showing what the sponsor, insurer and patient pay, including tests, routine care, travel, extended stay and complications. Do not assume that an investigational product or every protocol visit will be free.
Use the cost worksheet, then verify the exact product, evidence, legal route and written quotation with an independent qualified clinician.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.